Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? [2] (multiple letters)

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3430-3432

  Zaidi, Syed Z A ^a   Aljurf, Mahmoud ^a   Coiffier, Bertrand ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; RASBURICASE; RECOMBINANT PROTEIN; URATE OXIDASE;

ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; BURKITT LYMPHOMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HYDRATION; LETTER; LYMPHOBLASTOMA; LYMPHOMA; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; HYPERURICEMIA; LEUKEMIA; NONHODGKIN LYMPHOMA; NOTE;

COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; HYPERURICEMIA; LEUKEMIA; LYMPHOMA, NON-HODGKIN; RECOMBINANT PROTEINS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 4344668046     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.99.704     Document Type: Letter

References (0)